D-38/100

Is VivoSim Labs Inc (VIVS) a risky stock?

Sector: Biotechnology Price: $0.34 Composite: 38/100

As of July 30, 2026, Clavix grades VivoSim Labs Inc (VIVS) D- for risk, a composite score of 38 out of 100 on an A+ to F scale, which puts VIVS in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 30, 2026. Clavix regrades every trading day.

The five risk dimensions behind VIVS's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how VIVS scores on each, as of July 30, 2026.

Financial healthbalance sheet, margins, cash flow
46
News sentimentscored, sourced recent coverage
57
Macro exposuresensitivity to rates, dollar, oil
47
Sector resiliencestrength vs the broad market
67
Price stabilitydrawdown and volatility
0

What's moving VIVS's risk right now

Company-specific signals Clavix flags behind VIVS's current grade, drawn from recent news and filings as of July 30, 2026.

Earnings & results · raising risk

VivoSim reported a quarterly loss in its Fiscal Q4 results, underscoring that the company is still unprofitable. That keeps open the question of when, or if, the business will reach profitability.

Guidance · supporting the grade

Eli Lilly paid VivoSim a $5M milestone, and management guided for revenue growth above 500% in FY2027. VivoSim also posted its first commercial sales in China for NAMkind testing, opening a new geographic market.

Recent VIVS news

The latest headlines Clavix ingested for VivoSim Labs Inc, newest first. These feed the news-sentiment dimension of VIVS's grade.

What a D- grade means

On the Clavix A+ to F scale, VIVS's composite of 38 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell VIVS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.